Human kallikrein-2 gene polymorphism is associated with the occurrence of prostate cancer

Journal of Urology

Volumn 173, Issue 2, 2005, Pages 429-432

  Chiang, Chih Hung ^a   Hong, Chen Jee ^a   Chang, Yen Hwa ^a   Chang, Luke S ^a   Chen, Kuang Kuo ^a,b  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

Author keywords

Kallikreins; Polymorphism (genetics); Prostate; Prostatic neoplasms; Risk

Indexed keywords

KALLIKREIN; KALLIKREIN 2; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; GENOTYPE; HOMOZYGOSITY; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; TUMOR VOLUME;

EID: 12544258236     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000148964.92943.39     Document Type: Article

References (20)

1. Gronberg, H.: Prostate cancer epidemiology. Lancet, 361: 859, 2003
2. Cancer Registry Annual Report, Bureau of Health Promotion, Department of Health, Executive Yuan, Taiwan, Republic of China, 1999. Available at http://www.bhp.doh.gov.tw. Accessed April 15, 2004
3. Yousef, G. M. and Diamandis, E. P.: The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev, 22: 184, 2001
4. Rehault, S., Monget, P., Mazerbourg, S., Tremblay, R., Gutman, N., Gauthier, F. et al: Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem, 268: 2960, 2001
5. Frenette, G., Tremblay, R. R., Lazure, C. and Dube, J. Y.: Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer, 71: 897, 1997
6. Darson, M. F., Pacelli, A., Roche, P., Rittenhouse, H. G., Wolfert, R. L., Young, C. Y. et al: Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology, 49: 857, 1997
7. Partin, A. W., Catalona, W. J., Finlay, J. A., Darte, C., Tindall, D. J., Young, C. Y. et al: Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology, 54: 839, 1999
8. Becker, C., Piironen, T., Pettersson, K., Björk, T., Wojno, K. J., Oesterling, J. E. et al: Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol, 163: 311, 2000
9. Nam, R. K., Zhang, W. W., Trachtenberg, J., Diamandis, E., Toi, A., Emami, M. et al: Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol, 21: 2312, 2003
10. Haese, A., Becker, C., Noldus, J., Graefen, M., Huland, E., Huland, H. et al: Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus nonorgan confined growth of prostate cancer. J Urol, 163: 1491, 2000
11. Kumar, A., Mikolajczyk, S. D., Goel, A. S., Millar, L. S. and Saedi, M. S.: Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res, 57: 3111, 1997
12. Webber, M. M., Waghray, A. and Bello, D.: Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res, 1: 1089, 1995
13. Herrala, A., Kurkela, R., Porvari, K., Isomaki, R., Henttu, P. and Vihko, P.: Human prostate-specific glandular kallikrein is expressed as an active and an inactive protein. Clin Chem, 43: 279, 1997
14. Partin, A. W., Epstein, J. I., Cho, K. R., Gittelsohn, A. M. and Walsh, P. C.: Morphometric measurement of tumor volume and per cent of gland involvement as predictors of pathological stage in clinical stage B prostate cancer. J Urol, 141: 341, 1989
15. Carter, H. B.: Diagnosis and staging of prostate cancer. In: Campbell's Urology, 8th ed. Edited by P. C. Walsh, A. B. Retik, E. D. Vaughan, Jr. and A. J. Wein. Philadelphia: W. B. Saunders Co., vol. 4, sect. IX, chapt. 88, pp. 3055-3079, 2002
16. Fleshner, N. E., O'Sullivan, M. and Fair, W. R.: Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol, 158: 505, 1997
17. Whittemore, A. S., Keller, J. B. and Betensky, R.: Low-grade, latent prostate cancer volume: predictor of clinical cancer incidence? J Natl Cancer Inst, 83: 1231, 1991
18. Hautmann, S. H., Conrad, S., Henke, R. P., Erbersdobler, A., Simon, J., Straub, M. et al: Detection rate of histologically insignificant prostate cancer with systematic sextant biopsies and fine needle aspiration cytology. J Urol, 163: 1734, 2000
19. Mai, K. T., Isotalo, P. A., Green, J., Perkins, D. G., Morash, C. and Collins, J. P.: Incidental prostatic adenocarcinomas and putative premalignant lesions in TURP specimens collected before and after the introduction of prostate-specific antigen screening. Arch Pathol Lab Med, 124: 1454, 2000
20. Finlay, J. A., Evans, C. L., Day, J. R., Payne, J. K., Mikolajczyk, S. D., Millar, L. S. et al: Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology, 51: 804, 1998